Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(11 years from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9511046 | ABRAXIS BIOSCIENCE | Methods of treating pancreatic cancer |
Jan, 2034
(10 years from now) | |
US9511046
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating pancreatic cancer |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Dec 6, 2022 |
Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(11 years from now) | |
US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(11 years from now) |
Drugs and Companies using RIOCIGUAT ingredient
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class; Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9066957 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) | |
US9415008 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: Treatment of asthma
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9649280 | ETON | Composition comprising hydrocortisone |
May, 2034
(11 years from now) |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
Orphan Drug Exclusivity (ODE) | May 22, 2027 |
New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9566234 | INSMED INC | Systems for treating pulmonary infections |
Jan, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(11 years from now) | |
US9186346
(Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Apr 30, 2024 |
Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9550780
(Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
US9233959
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
US9296739
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) | |
US9814708
(Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
New Chemical Entity Exclusivity (NCE) | Apr 3, 2022 |
M | Jun 24, 2024 |
Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: October, 2023
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11517542 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11524007 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11517543 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11141388 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11213521 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11129826 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11123343 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10966974 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11524008 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11497721 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
US11478468 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11510918 | AXSOME | NA |
Nov, 2034
(11 years from now) | |
US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11311534 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10105327 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11364233 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11357744 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(11 years from now) | |
US9474731 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
US9421176 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(11 years from now) | |
US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10898453 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11433067 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9457023 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US11096937 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10966941 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11298351 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11090300 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10894047 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10786469 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10881657 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10874663 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10799497 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
US11058648 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10864209 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10806710 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US10786496 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11020389 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11185515 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10945973 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10596167 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US11439636 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11426401 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10772850 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11253491 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10548857 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11229640 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(11 years from now) | |
US10874665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10933034 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(11 years from now) | |
US10894046 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11191739 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10874664 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) | |
US11197839 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11147808 | AXSOME | Method of decreasing the fluctuation index of dextromethorphan |
Nov, 2034
(11 years from now) | |
US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US11141416 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(11 years from now) | |
US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(11 years from now) | |
US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 9, 2025 |
New Indication (I) | Jun 16, 2024 |
Orphan Drug Exclusivity (ODE) | Jan 9, 2027 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: January, 2024
Market Authorisation Date: 09 January, 2020
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 19, 2024 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 04 September, 2012
Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(11 years from now) | |
US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(11 years from now) | |
US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
New Indication (I) | Sep 14, 2024 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: April, 2026
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(11 years from now) | |
US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(11 years from now) | |
US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 20, 2024 |
New Indication (I) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: December, 2023
Market Authorisation Date: 20 December, 2019
Treatment: Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10624879 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
US11191753 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) | |
US9827231 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(11 years from now) |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(11 years from now) | |
US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(11 years from now) |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9487530 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
US10085992 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
US10966984 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) | |
US11040042 | G1 THERAP | Transient protection of normal cells during chemotherapy |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(11 years from now) | |
US11087354
(Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 10, 2022 |
New Indication (I) | Oct 28, 2025 |
M | Jul 28, 2025 |
Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(11 years from now) | |
US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(11 years from now) | |
US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(11 years from now) |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation
Dosage: SUSPENSION;INTRAOCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(11 years from now) | |
US9808530
(Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jan 24, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
Pediatric Exclusivity (PED) | Jul 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(11 years from now) |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 January, 1984
Treatment: NA
Dosage: INJECTABLE;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(11 years from now) |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 06 May, 2005
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9980974 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
US9492316 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 4, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
US9757406
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
US11116783
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
US10086011
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
New Strength (NS) | Mar 19, 2023 |
M | Apr 27, 2025 |
New Dosing Schedule (D) | Nov 15, 2022 |
New Patient Population (NPP) | Mar 19, 2023 |
Pediatric Exclusivity (PED) | May 15, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 28 June, 2016
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039728 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
US10004700 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) | |
US9283197 | BELCHER | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(11 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 29 July, 2014
Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical; Emergency treatment of allergic reactions (type i), including anaphylaxis; Induction and maintenance of mydriasis during intraocular surgery
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10040872 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(11 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
New Patient Population (NPP) | Sep 29, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(11 years from now) | |
US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(11 years from now) | |
US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(11 years from now) |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9884039 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(11 years from now) | |
US10272064 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(11 years from now) | |
US11433044 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(11 years from now) |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9486530 | EXELA PHARMA | Ganciclovir compositions and related methods |
Sep, 2034
(11 years from now) |
Drugs and Companies using GANCICLOVIR ingredient
Market Authorisation Date: 17 February, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) | |
US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 21 December, 2017
Treatment: Treating distributive shock with angiotensin ii; Treating septic shock with angiotensin ii; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) | |
US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 3, 2022 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10646456 | ADAMAS PHARMA | Methods of administering amantadine |
Jun, 2034
(11 years from now) | |
US10154971 | ADAMAS PHARMA | Methods of administering amantadine |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10039779 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10039779
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Dosing Schedule (D) | Nov 15, 2022 |
Orphan Drug Exclusivity (ODE) | Apr 7, 2024 |
Pediatric Exclusivity (PED) | Oct 7, 2024 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 10 October, 2014
Treatment: For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For the treatment of hepatitis c; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(11 years from now) | |
US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(11 years from now) | |
US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(11 years from now) | |
US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(11 years from now) | |
US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(11 years from now) |
Drugs and Companies using PALBOCICLIB ingredient
Market Authorisation Date: 01 November, 2019
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10093654 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
US9738625 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
US9732062 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Sep, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
New Chemical Entity Exclusivity (NCE) | Aug 1, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9540382
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(11 years from now) | |
US9296753
(Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(11 years from now) | |
US10463668 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
US10695350 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
US9795604 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jan 25, 2022 |
New Patient Population (NPP) | Aug 24, 2025 |
Orphan Drug Exclusivity (ODE) | Aug 2, 2024 |
Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 13 November, 2013
Treatment: Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 25, 2027 |
New Chemical Entity Exclusivity (NCE) | Nov 25, 2025 |
New Indication (I) | Jun 16, 2025 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: November, 2024
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11266661 | THERAPEUTICSMD INC | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(11 years from now) |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy
Dosage: INSERT;VAGINAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(11 years from now) | |
US9279794
(Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(11 years from now) |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient
Dosage: GAS;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9283209 | NOVARTIS PHARMS CORP | Oral formulations of deferasirox |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 30 March, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(11 years from now) | |
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Aug 18, 2024 |
M | Feb 24, 2025 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
Market Authorisation Date: 01 August, 2014
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and heart failure by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(11 years from now) | |
US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(11 years from now) | |
US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(11 years from now) | |
US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes
Dosage: SOLUTION;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028858 | MEDICINES360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
Mar, 2034
(11 years from now) |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10457666 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(11 years from now) | |
US9527833 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Feb 22, 2022 |
Orphan Drug Exclusivity (ODE) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
Market Authorisation Date: 22 September, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8999393 | ALMATICA | Sustained release formulations of lorazepam |
Jan, 2034
(10 years from now) |
Drugs and Companies using LORAZEPAM ingredient
Market Authorisation Date: 27 August, 2021
Treatment: Once daily treatment of anxiety disorder in adults
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(11 years from now) |
Drugs and Companies using LULICONAZOLE ingredient
Market Authorisation Date: 14 November, 2013
Treatment: NA
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9789257 | COVIS | Needle assisted injection device having reduced trigger force |
Feb, 2034
(11 years from now) |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 03 February, 2011
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(11 years from now) | |
US11484534 | ABBVIE INC | Methods for treating HCV |
Mar, 2034
(11 years from now) | |
US10286029
(Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(11 years from now) | |
US11484534
(Pediatric) | ABBVIE INC | Methods for treating HCV |
Sep, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 3, 2022 |
New Patient Population (NPP) | Apr 30, 2022 |
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
New Dosing Schedule (D) | Sep 26, 2022 |
M | Apr 10, 2023 |
Pediatric Exclusivity (PED) | Feb 3, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(11 years from now) | |
US9192608 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(11 years from now) | |
US9072781 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(11 years from now) |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 30 October, 2013
Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11090312 | ACERUS | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Mar, 2034
(11 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 28 May, 2014
Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9486406
(Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(11 years from now) | |
US9066856
(Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(11 years from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: NA
Dosage: SOLUTION;IRRIGATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(11 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: POWDER;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10881659 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) | |
US11045470 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
New Product (NP) | May 29, 2023 |
NCE-1 date: July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11344551 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(11 years from now) | |
US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 20, 2024 |
Orphan Drug Exclusivity (ODE) | Jul 19, 2026 |
M | Apr 10, 2023 |
Drugs and Companies using APREMILAST ingredient
Market Authorisation Date: 21 March, 2014
Treatment: Treatment of psoriasis using a dosage titration schedule; Treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of psoriatic arthritis using a dosage titration schedule; Treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248199 | GLOBAL BLOOD THERAPS | 1:1 adducts of sickle hemoglobin |
Jan, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 25, 2024 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; Treatment of sickle cell disease by administering voxelotor, as recited in claim 2
Dosage: TABLET, FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11060093 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US10465195 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US9828606 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
US10487330 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10435692 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 23, 2027 |
New Chemical Entity Exclusivity (NCE) | Nov 23, 2025 |
New Indication (I) | Oct 6, 2025 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9820938 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
US10344765 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) | |
US11162500 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 7, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10398791 | AAA USA NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9173851 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(11 years from now) | |
US9233077 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(11 years from now) | |
US9173851
(Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
US9233077
(Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
Pediatric Exclusivity (PED) | Feb 14, 2023 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9233077 | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(11 years from now) | |
US9173851 | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(11 years from now) | |
US9233077
(Pediatric) | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
US9173851
(Pediatric) | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
Pediatric Exclusivity (PED) | Feb 14, 2023 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 14 February, 2020
Treatment: NA
Dosage: GRANULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 7, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10357502 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(11 years from now) | |
US11253528 | EIRGEN | Stabilized modified release Vitamin D formulation and method of administering same |
Mar, 2034
(11 years from now) | |
US9861644 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(11 years from now) | |
US10300078 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(11 years from now) |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9676525 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(11 years from now) | |
US9669974 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(11 years from now) |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
US9993470 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11197853 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
New Combination (NC) | Mar 12, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561672 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US11400101 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10765686 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10758550 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10646500 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10548907 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10016443 | GLENMARK SPECIALTY | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10517880 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US9750754 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US9078923 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US9937189 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US10376526 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) | |
US9370483 | GLENMARK SPECIALTY | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jan 13, 2025 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate; Method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jan 16, 2023 |
New Product (NP) | Sep 20, 2022 |
New Chemical Entity Exclusivity (NCE) | Dec 5, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10406332 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Mar, 2034
(11 years from now) | |
US10232152 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Nov, 2034
(11 years from now) |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT;IMPLANTATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9233118 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
US9089587 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
US9233117 | GALDERMA LABS LP | Treatment of inflammatory lesions of rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
US9782425 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) | |
US10206939 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(11 years from now) |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11013703 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(11 years from now) | |
US10206895 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(11 years from now) |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2014
Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy
Dosage: SOLUTION;INTRATHECAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 5, 2024 |
New Indication (I) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant
Dosage: SPRAY;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11160786 | APRECIA PHARMS | Rapid disperse dosage form |
Mar, 2034
(11 years from now) | |
US9669009 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(11 years from now) | |
US9339489 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(11 years from now) |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 31 July, 2015
Treatment: Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam; Method of administering levetiracetam under fed conditions
Dosage: TABLET, FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 August, 2015
Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2016
Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9050263 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(11 years from now) | |
US11135172 | REDHILL | Rifabutin-based compositions and methods for treating Helicobacter pylori infection |
Feb, 2034
(11 years from now) | |
US9498445 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(11 years from now) | |
US10238606 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(11 years from now) | |
US9603806 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(11 years from now) |
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of h. pylori infection in adults
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Aug, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 23, 2025 |
New Indication (I) | Jun 18, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 23, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating epithelioid sarcoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8962829 | CHIMERIX | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10112909 | CHIMERIX | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(11 years from now) | |
US10487061 | CHIMERIX | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(11 years from now) | |
US9371344 | CHIMERIX | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jun 4, 2024 |
Orphan Drug Exclusivity (ODE) | Jun 4, 2028 |
Drugs and Companies using BRINCIDOFOVIR ingredient
Market Authorisation Date: 04 June, 2021
Treatment: Method of treating human smallpox disease
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(11 years from now) | |
US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11234938 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
US11446252 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
US10624855 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: NA
Dosage: TABLET, CHEWABLE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9295675 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(11 years from now) | |
US9662340 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(11 years from now) | |
US8785426 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(11 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 04 June, 2014
Treatment: Method for transdermal delivery of testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9296782 | GILEAD SCIENCES INC | Inhibitors of hepatitis C virus |
Jul, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
US11116783
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028912 | CELATOR PHARMS | Method of lyophilizing liposomes |
Sep, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 3, 2024 |
New Patient Population (NPP) | Mar 30, 2024 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(11 years from now) | |
US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 13, 2026 |
Orphan Drug Exclusivity (ODE) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(11 years from now) | |
US9539218
(Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Aug 23, 2024 |
M | Mar 10, 2023 |
Pediatric Exclusivity (PED) | Apr 11, 2023 |
Drugs and Companies using RIVAROXABAN ingredient
Market Authorisation Date: 01 July, 2011
Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10292389 | DR REDDYS LABS SA | Pediculicidal composition |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 23 February, 2016
Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; A method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10076614 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2034
(11 years from now) |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: NA
Dosage: SUSPENSION;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10881798 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Feb, 2034
(11 years from now) | |
US11160751 | ANTARES PHARMA INC | Hematocrit modulation through needle assisted jet injection of testosterone |
Oct, 2034
(11 years from now) |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9889144 | SUN PHARM | Abiraterone acetate formulation and methods of use |
Mar, 2034
(11 years from now) | |
US10292990 | SUN PHARM | Abiraterone steroid formulation |
May, 2034
(11 years from now) |
Drugs and Companies using ABIRATERONE ACETATE ingredient
Market Authorisation Date: 22 May, 2018
Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8906898 | CUBIST PHARMS LLC | Solid forms of ceftolozane |
May, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11278622 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(11 years from now) | |
US8968753 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(11 years from now) | |
US10420841 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(11 years from now) | |
US9872906 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(11 years from now) | |
US9320740 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(11 years from now) | |
US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(11 years from now) | |
US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 19, 2019 |
New Patient Population (NPP) | Apr 21, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Dec 19, 2024 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associated bacterial pneumonia (vabp); Treatment of complicated urinary tract infection, including pyelonephritis; Treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9713611 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(11 years from now) | |
US9452163 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(11 years from now) | |
US9486451 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(11 years from now) | |
US10092559 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(11 years from now) | |
US9132096 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(11 years from now) |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10688291 | ZUREX PHARMA | Medical skin applicator apparatus |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 26, 2022 |
M | Jun 24, 2024 |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 26 April, 2019
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SOLUTION;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 12, 2024 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
Click on the highlighted region to filter.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9765379 | GENENTECH, INC. | Harvest operations for recombinant proteins |
Mar, 2034
(11 years from now) | |
US10829732 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(11 years from now) | |
US10017732 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(11 years from now) |
Ingredients: RANIBIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9499614 | ABBVIE INC. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
Mar, 2034
(11 years from now) | |
US9550826 | ABBVIE INC. | Glycoengineered binding protein compositions |
Nov, 2034
(11 years from now) |
Ingredients: ADALIMUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US10676710 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(11 years from now) | |
US9441035 | GENENTECH, INC. | Cell culture media and methods of antibody production |
Apr, 2034
(11 years from now) |
Ingredients: BEVACIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US11332771 | REGENERON PHARMACEUTICALS, INC. | Serum-free cell culture medium |
Mar, 2034
(11 years from now) | |
USD858754 | REGENERON PHARMACEUTICALS, INC. | Syringe cap |
Sep, 2034
(11 years from now) |
Ingredients: AFLIBERCEPT
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US10677803 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(11 years from now) | |
US11280794 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(11 years from now) | |
US10119976 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(11 years from now) | |
US10676772 | BIOGEN INC. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
Aug, 2034
(11 years from now) | |
US9994968 | BIOGEN INC. | Electrochemical etching apparatus |
Aug, 2034
(11 years from now) |
Ingredients: NATALIZUMAB
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic